Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Management of coronary heart disease risk factors and progression with calcium channel blockers
Autore:
Pieper, JA;
Indirizzi:
Univ N Carolina, Sch Pharm, Div Pharmacotherapy, Chapel Hill, NC 27599 USAUniv N Carolina Chapel Hill NC USA 27599 erapy, Chapel Hill, NC 27599 USA
Titolo Testata:
PHARMACOTHERAPY
fascicolo: 9, volume: 21, anno: 2001,
parte:, 2 supplemento:, S
pagine: 195S - 208S
SICI:
0277-0008(200109)21:9<195S:MOCHDR>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
CHRONIC STABLE ANGINA; ISOLATED SYSTOLIC HYPERTENSION; ACC/AHA/ACP-ASIM GUIDELINES; ASSOCIATION TASK-FORCE; CHOLESTEROL-FED RABBIT; RANDOMIZED TRIAL; EUROPEAN TRIAL; OLDER PATIENTS; BETA-BLOCKERS; ATHEROSCLEROSIS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Pieper, JA Univ N Carolina, Sch Pharm, Div Pharmacotherapy, Beard Hall,CB 7360, Chapel Hill, NC 27599 USA Univ N Carolina Beard Hall,CB 7360 Chapel Hill NC USA 27599 USA
Citazione:
J.A. Pieper, "Management of coronary heart disease risk factors and progression with calcium channel blockers", PHARMACOTHE, 21(9), 2001, pp. 195S-208S

Abstract

The death rate from coronary heart disease (CHD) declined by 25% in the United States during 1987-1997, but the actual number of deaths fell by only 9%. Modifiable risk factors for CHD include hypertension, elevated low-density lipoprotein cholesterol, reduced high-density lipoprotein cholesterol, cigarette smoking, and diabetes. Several randomized clinical trials demonstrated that calcium channel blockers reduce the frequency of strokes in patients with hypertension, with particular benefit observed in patients with both hypertension and diabetes. Results of a meta-analysis suggest that calcium channel blockers are similar to P-blockers in preventing death or myocardial infarction and in improving exercise tolerance among patients with established CHD. In addition, amlodipine, a long-acting dihydropyridine, was reported to reduce nonfatal vascular events and major vascular procedures in patients with angina. Ongoing clinical trials are comparing amlodipine with an angiotensin-converting enzyme inhibitor for slowing the onset and progression of coronary artery plaque and cardiovascular events.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/03/20 alle ore 15:29:33